BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB IN STK11-MUTATED ADVANCED/METASTATIC NON-SMALL LUNG CANCER (NSCLC)
Bergen, Norway, 9 November 2021 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for bemcentinib in combination with an anti-PD-(L)1 agent as treatment for patients with STK11 altered advanced/metastatic NSCLC patients without actionable mutations. Fast Track designation is intended to facilitate the development and review of drugs used to treat serious conditions and to fill an unmet medical